169 related articles for article (PubMed ID: 24813799)
21. Back to basics: PCSK9 as a new target for the LDL receptor.
Corral P
Arq Bras Cardiol; 2014 Jan; 102(1):e5-8. PubMed ID: 24652095
[No Abstract] [Full Text] [Related]
22. PCSK9 inhibition: the next statin?
Vogel RA
J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426
[No Abstract] [Full Text] [Related]
23. Genetics: a gene of rare effect.
Hall SS
Nature; 2013 Apr; 496(7444):152-5. PubMed ID: 23579660
[No Abstract] [Full Text] [Related]
24. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
Shimada YJ; Cannon CP
Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
[TBL] [Abstract][Full Text] [Related]
25. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
[No Abstract] [Full Text] [Related]
26. PCSK9 and its modulation.
Cui CJ; Li S; Li JJ
Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750
[TBL] [Abstract][Full Text] [Related]
27. PCSK9: a key modulator of cardiovascular health.
Seidah NG; Awan Z; Chrétien M; Mbikay M
Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
[TBL] [Abstract][Full Text] [Related]
28. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
Awan Z; Baass A; Genest J
Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
[TBL] [Abstract][Full Text] [Related]
29. [Hypercholesterolemia: Monoclonal antibodies safe and effective].
Windler E
Dtsch Med Wochenschr; 2015 May; 140(11):785-6. PubMed ID: 26080713
[No Abstract] [Full Text] [Related]
30. Predicting the Overuse of PCSK-9 Inhibitors.
Rodriguez-Gutierrez R; Shah ND; Montori VM
JAMA; 2015 Nov; 314(18):1909-10. PubMed ID: 26547456
[No Abstract] [Full Text] [Related]
31. Genetics. Simple genetics for a complex disease.
Cohen JC; Hobbs HH
Science; 2013 May; 340(6133):689-90. PubMed ID: 23661745
[TBL] [Abstract][Full Text] [Related]
32. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
33. PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy.
Denegri A; Petrova-Slater I; Pasotti E; Rossi MG; Pedrazzini GB; Moccetti T; Moccetti M
J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):237-44. PubMed ID: 26855411
[TBL] [Abstract][Full Text] [Related]
34. New weapon in fighting atherosclerosis: effective inhibition of circulating low density lipoprotein cholesterol.
Ginter E; Simko V
Bratisl Lek Listy; 2014; 115(12):741-2. PubMed ID: 25520219
[TBL] [Abstract][Full Text] [Related]
35. PCSK9: an emerging target for treatment of hypercholesterolemia.
Duff CJ; Hooper NM
Expert Opin Ther Targets; 2011 Feb; 15(2):157-68. PubMed ID: 21204732
[TBL] [Abstract][Full Text] [Related]
36. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
37. PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
EBioMedicine
EBioMedicine; 2015 Dec; 2(12):1835. PubMed ID: 26844247
[No Abstract] [Full Text] [Related]
38. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
Ballantyne CM; Neutel J; Cropp A; Duggan W; Wang EQ; Plowchalk D; Sweeney K; Kaila N; Vincent J; Bays H
Am J Cardiol; 2015 May; 115(9):1212-21. PubMed ID: 25784512
[TBL] [Abstract][Full Text] [Related]
39. Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Liu MH
Int J Cardiol; 2015 Sep; 195():212-4. PubMed ID: 26048378
[No Abstract] [Full Text] [Related]
40. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
